Perfectus Biomed, a company providing standard and customised microbiological testing services, and Medilink member, has announced its merger with Wyoming-based laboratory, Extherid Biosciences.
The merger brings together a breadth of industry experience and expands Perfectus Biomed's service offering and geographical reach. Prior to this formation, both CROs focused on customised testing that supported their client’s product development and regulatory journeys. Clients with multinational needs requiring such support will continue to receive the quality they have come to know and expect from Perfectus Biomed but with added expertise in both geographies, increasing testing capabilities.
In the UK division, services are UKAS accredited, GLP compliant and ISO 90001 certified. These include accredited biofilm testing, microbiology, molecular biology, cell culture and virology and are offered to medical devices, wound care, pharmaceutical, cosmetic and biocidal sectors.
The U.S. facility’s expertise lies in experimental therapeutics and pre-clinical infectious disease research through customised tissue models. The facility provides specialist research for the medical device, urogenital health, wound care, inflammation and bio-compatibility sectors.
Dr Samantha Westgate PhD, CEO of Perfectus Biomed Group, said: “We are delighted to be merging with Extherid Biosciences and look forward to offering our clients an enhanced service and an expanded geographical offering."
Effective from 1st June 2020, Extherid Biosciences will be known as Perfectus Biomed LLC and the UK subsidiary will continue to be known as Perfectus Biomed Limited.
For more information, please click here.